Bone histologic response to deferoxamine in aluminum-related bone disease.

@article{Andress1987BoneHR,
  title={Bone histologic response to deferoxamine in aluminum-related bone disease.},
  author={Dennis L. Andress and H G Nebeker and Susan M. Ott and David B. Endres and Allen C. Alfrey and Eduardo A. Slatopolsky and Jack W. Coburn and Donald J. Sherrard},
  journal={Kidney international},
  year={1987},
  volume={31 6},
  pages={1344-50}
}
We have examined the changes in bone histology in 28 uremic patients after long-term treatment with the aluminum chelator, deferoxamine. Marked declines in stainable bone-surface aluminum were associated with increases in bone formation rate and osteoblastic osteoid following deferoxamine. The increased bone formation resulted from increases in bone apposition and length of double-tetracycline labels, the latter being highly correlated with the increase in osteoblastic osteoid (r = 0.85). While… CONTINUE READING